ArticleFrontiers in bioinformatics2025
Integrative multi-omics study identifies sex-specific molecular signatures and immune modulation in bladder cancer.
Article in Frontiers in bioinformatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Circulating Tumor Function: A Systems Biology Framework for Liquid Biopsy in Genitourinary Cancers.Genes · 2026Review
- Integrative microRNA and transcriptome analysis reveals sex-specific molecular divergence in human bladder cancer.Biology of sex differences · 2026Article
- Machine learning-based determination of sex-related bladder cancer biomarkers.Frontiers in bioinformatics · 2026Article
- Machine-learning-based determination of sex-related bladder cancer biomarkers.bioRxiv : the preprint server for biology · 2025Article
- Beyond Visualization: Advanced Imaging, Theragnostics and Biomarker Integration in Urothelial Bladder Cancer.Cancers · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Introduction: Bladder cancer shows distinct sex-related patterns, with male patients experiencing significantly higher incidence and female patients facing poorer survival outcomes. This study aimed to investigate the biological mechanisms underlying these differences using integrative multi-omics analysis. Methods: We analyzed bladder cancer data from TCGA and GTEx, including genomic mutations, gene expression profiles, and clinical information. We performed protein-protein interaction analysis, pathway enrichment, survival analysis, and immune cell correlation. Results: We identified androgen receptor (AR)-related pathways as uniquely enriched in male-specific hub genes, while the Wnt signaling pathway was enriched in female-specific hub genes. In total, 14 male-specific hub genes showed significant sex-biased survival associations, including known markers-DLGAP5, SOX2, LAMA2, and COL5A2-and novel ones such as ERCC5, NID1, ANK2, and others. For females, three hub genes-RAD51C, COL22A1, and COL5A2-were identified as female-specific with survival associations. Additionally, four male-specific hub genes-DAXX, IKBKB, PDGFRA, and PPARG-were immune-related and showed sex-differential correlations with immune cell infiltration, with three of them associated with AR signaling regulation. Discussion: These findings provide new insights into the molecular basis of sex differences in bladder cancer and could pave the way for more personalized and effective therapeutic strategies tailored to male and female patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.